Open access
Aug 2026
Combination therapy of RAS inhibition and glucagon-like peptide-1 receptor agonist improves a marker of kidney fibrosis in people with type 2 diabetes.
In people with T2D receiving combination therapy with RASi + GLP-1 RA, urinary C3M levels remained stable, whereas levels decreased with RASi monotherapy, suggesting altered kidney ECM turnover.
A. Møller, Stefanie Thöni, Felix Keller et al.
· American Journal of Physiolo... · 0 citations